ABOUT RESVINET FOUNDATION
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries.
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.
Advances in RSV vaccine development
April 2018 - Advances in knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have revolutionized RSV vaccine development by providing a new target for preventive interventions. It is explained in this video, which was made by Djonie Jacobsen; Nienke Mombarg and Charlotte Wiersma, students from De Streek school in Ede, The Netherlands.
ReSViNET is proud to announce new publication in Lancet Infectious Diseases
26 June 2018 - We are happy to share with you that our manuscript "The RSV Vaccine Landscape: Lessons from the Graveyard and Promising Candidates” has been published online in the Lancet Infectious Diseases.
The aim of the manuscript is to give a comprehensive overview of vaccine candidates in clinical development, including maternal vaccine candidates. We hope you will enjoy reading the manuscript and look forward to receiving any questions or feedback. www.ncbi.nlm.nih.gov/pubmed/29914800
Official Launch of the ReSViNET Foundation
ZEIST, THE NETHERLANDS, 15 May 2018 – Today, we proudly announce the Official Launch of the ReSViNET Foundation as a registered not-for-profit entity under Dutch law. After 4 years of building and shaping the network and months of preparation, the ReSViNET Foundation has officially been founded.
As a foundation ReSViNET is now a financially and otherwise independent regulated entity which represents a major milestone for the entire ReSViNET project. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward.
We are exceptionally proud to be the first official Respiratory Syncytial Virus (RSV) foundation and aim to foster global collaboration among ...
Beautiful impression video - RSV Vaccines for the World conference 2017
ReSViNET Global partners
PAPER OF THE MONTH
THE SIGNIFICANCE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) IN CHILDREN FROM GHANA WITH ACUTE LOWER RESPIRATORY TRACT INFECTION: A MOLECULAR EPIDEMIOLOGY ANALYSIS.
Obodai E, Odoom JK, Adiku T, Goka B, Wolff T, Biere B, Schweiger B, Reiche J.
Summary: The molecular epidemiology of RSV infection is increasingly thought to be essential to understand how the virus spreads around the world every year. RSV molecular epidemiology also informs developers of therapeutics about potential sensitivity or resistance of the virus to specific drugs. Altogether, data of about 1000 specimens have been published, most from developed countries. The World Health Organization has started a pilot to perform RSV surveillance, probably including viral sequencing. Data from poor resource settings have been prioritized. To that end it is important to note this paper form researchers from Ghana and Germany who were able to provide valuable sequence data from a study performed in 2006-2014 in which 127 RSV positive children were included. The results show the evaluation of RSV-A (ON1) and RSV-B strains (BA9) in Ghana. These data will add significantly to our understanding of viral behavior over time in low and middle income countries (LMIC)